Why ResMed's Rally Is Just Getting Started

Summary

ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns.
The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates.
Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors.
With 1 billion people suffering from sleep apnea and only a fraction using ResMed's devices, the growth potential remains enormous.

JHVEPhoto

Introduction

It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is ResMed (NYSE:RMD), a fast-growing healthcare company.

My most recent article on this company

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":350847955034160,"tweetId":"350847955034160","gmtCreate":1726673435000,"gmtModify":1726678971006,"author":{"id":10000000000010896,"idStr":"10000000000010896","authorId":10000000000010896,"authorIdStr":"10000000000010896","name":"Leo Nelissen","avatar":"https://community-static.tradeup.com/news/8c07a36112cfcef2038947477661e164","vip":8,"userType":8,"introduction":".","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/76c963c6e22c772f2be0255a5faca14e"}],"coverImages":[{"img":"https://static.tigerbbs.com/76c963c6e22c772f2be0255a5faca14e"}],"title":"Why ResMed's Rally Is Just Getting Started","html":"<html><head></head><body><h2>Summary</h2>\n<ul>\n <li>ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns.</li>\n <li>The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates.</li>\n <li>Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors.</li>\n <li>With 1 billion people suffering from sleep apnea and only a fraction using ResMed's devices, the growth potential remains enormous.</li>\n</ul>\n<p></p> \n<img src=\"https://static.tigerbbs.com/76c963c6e22c772f2be0255a5faca14e\"> \n<p class=\"item-caption\"> </p> \n<p class=\"item-credits\">JHVEPhoto</p>\n<p></p> \n<h2>Introduction</h2> \n<p>It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is <strong>ResMed (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/RMD\">RMD</a></span>)</strong>, a fast-growing healthcare company.</p> \n<p>My most recent <a href=\"https://seekingalpha.com/article/4644927-resmed-earnings-down-60-percent-tremendous-long-term-potential\">article</a> on this company</p></body></html>","htmlText":"<html><head></head><body><h2>Summary</h2>\n<ul>\n <li>ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns.</li>\n <li>The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates.</li>\n <li>Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors.</li>\n <li>With 1 billion people suffering from sleep apnea and only a fraction using ResMed's devices, the growth potential remains enormous.</li>\n</ul>\n<p></p> \n<img src=\"https://static.tigerbbs.com/76c963c6e22c772f2be0255a5faca14e\"> \n<p class=\"item-caption\"> </p> \n<p class=\"item-credits\">JHVEPhoto</p>\n<p></p> \n<h2>Introduction</h2> \n<p>It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is <strong>ResMed (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/RMD\">RMD</a></span>)</strong>, a fast-growing healthcare company.</p> \n<p>My most recent <a href=\"https://seekingalpha.com/article/4644927-resmed-earnings-down-60-percent-tremendous-long-term-potential\">article</a> on this company</p></body></html>","text":"Summary ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates. Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors. With 1 billion people suffering from sleep apnea and only a fraction using ResMed's devices, the growth potential remains enormous. JHVEPhoto Introduction It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is ResMed (NYSE:RMD), a fast-growing healthcare company. My most recent article on this company","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/350847955034160","repostId":0,"isVote":1,"tweetType":1,"viewCount":131,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["RMD"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":739,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/350847955034160"}